Conv. Plasma
Nigella Sativa

All favipiravir studies
Meta analysis
study COVID-19 treatment researchFavipiravirFavipiravir (more..)
Melatonin Meta
Azvudine Meta Metformin Meta
Bromhexine Meta
Budesonide Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Famotidine Meta Nitazoxanide Meta
Favipiravir Meta Paxlovid Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality -56% Improvement Relative Risk Ventilation 90% Adjusted discharge ratio 49% Favipiravir  Alamer et al.  LATE TREATMENT Is late treatment with favipiravir beneficial for COVID-19? Retrospective 456 patients in Saudi Arabia Lower ventilation (p<0.0001) and higher discharge (p<0.0001) Alamer et al., Current Medical Researc.., May 2021 Favors favipiravir Favors control

Effectiveness and safety of favipiravir compared to supportive care in moderately to critically ill COVID-19 patients: a retrospective study with propensity score matching sensitivity analysis

Alamer et al., Current Medical Research and Opinion, doi:10.1080/03007995.2021.1920900
May 2021  
  Source   PDF   All Studies   Meta AnalysisMeta
Retrospective 234 favipiravir and 223 control patients in Saudi Arabia, showing shorter time to discharge and lower progression to ventilation, but no significant difference in mortality.
risk of death, 56.0% higher, HR 1.56, p = 0.26, treatment 12 of 233 (5.2%), control 21 of 223 (9.4%), adjusted per study, day 90.
risk of mechanical ventilation, 90.0% lower, HR 0.10, p < 0.001, treatment 4 of 218 (1.8%), control 27 of 165 (16.4%), NNT 6.9, adjusted per study.
adjusted discharge ratio, 49.0% lower, RR 0.51, p < 0.001, treatment 221, control 201, adjusted per study, inverted to make RR<1 favor treatment.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Alamer et al., 19 May 2021, retrospective, Saudi Arabia, peer-reviewed, 18 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperFavipiravirAll
Effectiveness and safety of favipiravir compared to supportive care in moderately to critically ill COVID-19 patients: a retrospective study with propensity score matching sensitivity analysis
Ahmad Alamer, Ahmed A Alrashed, Mashael Alfaifi, Bandar Alosaimi, Fatimah Alhassar, Malak Almutairi, Jude Howaidi, Wedad Almutairi, Yahya Mohzari, Tarek Sulaiman, Ahmed Al-Jedai, Hamdan N Alajami, Fatima Alkharji, Ali Alsaeed, Alaa H Alali, Abdullah A Baredhwan, Ivo Abraham, Abdulaziz S Almulhim
Current Medical Research and Opinion, doi:10.1080/03007995.2021.1920900
Introduction: Favipiravir is a repurposed drug to treat coronavirus 2019 (COVID-19). Due to a lack of available real-world data, we assessed its effectiveness and safety in moderately to critically ill COVID-19 patients. Methods: This retrospective study was conducted in two public/specialty hospitals in Saudi Arabia. We included patients !18 years) admitted April-August 2020 with confirmed SARS-CoV-2 diagnosed by real-time polymerase chain reaction (RT-PCR) from nasopharyngeal swab. Patients received either favipiravir (1800 mg or 1600 mg twice daily loading dose, followed by 800 mg or 600 mg twice daily) or supportive-care treatment. Patients were excluded if they were outside the study period, classified as having a mild form of the disease per WHO criteria, or had an incomplete patient file. Kaplan-Meier (KM) models were used to estimate median time to discharge. Discharge ratios, progression to mechanical ventilation, and mortality outcomes were estimated across the severity spectrum using Cox proportional-hazards models. As a sensitivity analysis, we performed propensity score-matching (PSM) analysis. Results: Overall, median time to discharge was 10 days (95%CI ¼ 9-10) in the favipiravir arm versus 15 days (95%CI ¼ 14-16) in the supportive-care arm. The accelerated discharge benefit was seen across the COVID-19 spectrum of severity. The adjusted discharge ratio was 1.96 (95%CI ¼ 1.56-2.46). Progression to mechanical ventilation was slower with favipiravir (HR adj ¼ 0.10, 95%CI ¼ 0.04-0.29). There was no significant effect on mortality (HR adj ¼ 1.56, 95%CI ¼ 0.73-3.36). There was a statistically non-significant trend toward worse outcomes in the critical category (HR adj ¼ 2.80, 95%CI ¼ 0.99-7.89). Age was an independent risk factor for mortality in mechanically ventilated patients. PSM analyses confirmed these findings. Conclusion: Favipiravir was associated with clinical benefits, including accelerated discharge rate and less progression to mechanical ventilation; however, no overall mortality benefits were seen across the severity spectrum.
Author contributions Conceptualization: Ahmad Alamer and Ahmad A Alrashed; methodology: Ahmad Alamer and Ivo Abraham; software: Ahmad Alamer; validation: Abdulaziz S. Alulhmim and Ivo Abraham; formal analysis: Ahmad Alamer; data curation: Fatima Alhassar, Malak M. Almutairi, Jude Howaidi, Wedad Almutairi, and Mashael Alfaifi; writing of original draft preparation: Ahmad Alamer and Abdulaziz S. Alulhmim; writing, reviewing, and editing: Ahmad Alamer, Abdulaziz S. Alulhmim, Ivo Abraham, Ahmad A Alrashed, Bandar Alosaimi, Yahya Mohzari, Tarek Sulaiman, Ahmed AlJedai, Alaa H. Alali, and Abdulla Baradwan; visualization: Ahmad Alamer; supervision: Ahmad Alamer and Ivo Abraham; project administration: Ahmad Alamer, Mashael Alfaifi, Ahmad A Alrashed, and Yahya Mohzari. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, declare their responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.
Alamer, Al, None
Beigel, Tomashek, Dodd, Remdesivir for the treatment of Covid-19 -preliminary report. Reply, N Engl J Med
Bradburn, Clark, Love, Survival analysis part II: multivariate data analysis-an introduction to concepts and methods, Br J Cancer
Cai, Yang, Liu, Experimental treatment with favipiravir for COVID-19: an open-label control study, Engineering
Chen, Zhang, Huang, Favipiravir versus arbidol for COVID-19: a randomized clinical trial, medRxiv, doi:10.1101/2020.03.17.20037432
D'agostino, Propensity scores in cardiovascular research, Circulation
Deeks, Higgins, Altman, Analysing data and undertaking meta-analyses
Furuta, Gowen, Takahashi, Favipiravir (T-705), a novel viral RNA polymerase inhibitor, Antiviral Res
Harris, Taylor, Minor, The REDCap consortium: building an international community of software platform partners, J Biomed Inf
Horby, Lim, Emberson, Dexamethasone in hospitalized patients with COVID-19, N Engl J Med
Huang, Wang, Li, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet
Irie, Nakagawa, Fujita, Pharmacokinetics of favipiravir in critically ill patients with COVID-19, Clin Transl Sci
Lumley, Analysis of complex survey samples, J Stat Soft
Mitra, Reiter, A comparison of two methods of estimating propensity scores after multiple imputation, Stat Methods Med Res
Network, The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies
Pan, Peto, Henao-Restrepo, Repurposed antiviral drugs for COVID-19 -interim WHO Solidarity trial results, N Engl J Med
Pardo, Shukla, Chamarthi, The journey of remdesivir: from Ebola to COVID-19, DIC
Parr, Time to reassess Tocilizumab's role in COVID-19 pneumonia, JAMA Intern Med
Petrosillo, Viceconte, Ergonul, COVID-19, SARS and MERS: are they closely related? Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases, Clin Microbiol Infect
Pilkington, Pepperrell, Hill, A review of the safety of favipiravir -a potential treatment in the COVID-19 pandemic?, J Virus Eradic
Pishgar, Greifer, Leyrat, MatchThem: matching and weighting after multiple imputation
Rafi, Bhattacharje, Al-Khafaji, Combination of QSAR, molecular docking, molecular dynamic simulation and MM-PBSA: analogues of lopinavir and favipiravir as potential drug candidates against COVID-19, J Biomol Struct Dyn
Rattanaumpawan, Jirajariyavej, Lerdlamyong, Realworld experience with favipiravir for treatment of COVID-19 in Thailand: results from a multi-center observational study, medRxiv
Scheike, Zhang, Analyzing competing risk data using the R timereg package, J Stat Soft
Sissoko, Laouenan, Folkesson, Experimental treatment with favipiravir for ebola virus disease (the JIKI Trial): a historically controlled, single-arm proof-of-concept trial in Guinea, PLoS Med
Sterne, White, Carlin, Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls, BMJ
Therneau, A package for survival analysis in R
Vaira, Deiana, Fois, Objective evaluation of anosmia and ageusia in COVID-19 patients: single-center experience on 72 cases, Head Neck
Vaira, Hopkins, Salzano, Olfactory and gustatory function impairment in COVID-19 patients: Italian objective multicenter-study, Head Neck
Van Buuren, Groothuis-Oudshoorn, mice: Multivariate imputation by chained equations in R, J Stat Soft
Vassar, Holzmann, The retrospective chart review: important methodological considerations, J Educ Eval Health Prof
Wang, Chen, Tissue distributions of antiviral drugs affect their capabilities of reducing viral loads in COVID-19 treatment, Eur J Pharmacol
Wooding, Bach, Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks, Clin Microbiol Infect
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of over 100,000 datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop